Table 1.
Baseline characteristics of patients from both CD22 and bispecific CD19/22 CAR T cell cohorts included in the study
| Characteristic | CD22 CAR T cells (n = 40) |
CD19/22 CAR T cells (n = 15) |
||||
|---|---|---|---|---|---|---|
| Cryopreserved | Fresh | p value | Cryopreserved | Fresh | p value | |
| n | 21 | 19 | 11 | 8 | ||
| Gender (%male) | 57% | 84% | 0.09 | 45% | 38% | 1 |
| Median age (yrs) | 13 | 12 | 0.96 | 28 | 17 | 0.41 |
| Median weight (kg) | 47 | 50 | 0.94 | 67 | 52 | 0.12 |
| Race | 67% White | 63% White | 1 | 54% White | 63% White | 1 |
| 19% Asian | 5% Asian | 0.35 | 18% Black | 0% Black | 0.49 | |
| 5% multiple | 11% multiple | 0.60 | 9% Asian | 0% Asian | 1 | |
| 10% unknown | 21% unknown | 0.40 | 18% unknown | 38% unknown | 0.60 | |
| Ethnicity | 29% Hispanic | 39% Hispanic | 0.52 | 27% Hispanic | 75% Hispanic | 0.07 |
| Diagnosis | 100% ALL | 89% ALL, 6% CML w/ALL blast crisis, 6% B-LLy | 1 | 100% ALL | 100% ALL | 1 |
| Median disease burden (percent MNCs in BM) | 48% | 40% | 0.93 | 0.70% | 25.15% | 0.03 |
| Disease burden M | M1 24%, M2 9.5%, M3 67% | M1 26%, M2 16%, M3 58% | 0.79 | M1 73%, M2 9%, M3 18% | M1 38%, M2 13%, M3 50% | 0.28 |
| CNS status | 95% CNS1, 5% CNS2 | 100% CNS1 | 1 | 100% CNS1 | 100% CNS1 | 1 |
| Extramedullary disease | 5/21 (24%) | 3/19 (16%) | 0.70 | 4/11 (36%) | 1/8 (13%) | 0.34 |
| Prior HSCT | 10/21 (48%) | 9/19 (47%) | 0.99 | 7/11 (64%) | 3/8 (38%) | 0.37 |
| Prior CAR T therapy | 12/21 (57%) | 14/19 (74%) | 0.33 | 2/11 (18%) | 2/8 (25%) | 1 |
| Median number of prior treatments | 6 | 6 | 0.41 | 3 | 4.5 | 0.16 |
MNC = mononuclear cell, BM = bone marrow, HSCT = hematopoietic stem cell transplant, ALL = acute lymphoblastic leukemia, CML = chronic myelogenous leukemia, BLLy = B-lymphoblastic lymphoma, CNS = central nervous system.
Statistically significant p-values are shown in bold.